Pulmonary Arterial Hypertension (PAH) Medicine Market Report

Global Pulmonary Arterial Hypertension (PAH) Medicine Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 01, 2022
  • PAGES：195
  • REPORT CODE：GMM785464
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Pulmonary Arterial Hypertension (PAH) Medicine market report explains the definition, types, applications, major countries, and major players of the Pulmonary Arterial Hypertension (PAH) Medicine market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Bayer HealthCare

    • Pfizer

    • Actelion Pharmaceuticals

    • United Therapeutics Corporation

    • GlaxoSmithKline

    • Gilead Sciences

    • Arena Pharmaceuticals

    By Type:

    • Endothelin Receptor Antagonists (ERA)

    • Prostacyclin And Prostacyclin Analogs

    • Phosphodiesterase 5 (PDE-5)

    • Soluble Guanylate Cyclase (SGC) Stimulators

    By End-User:

    • Secondary Pulmonary Hypertension (SPH)

    • Primary Pulmonary Hypertension (PPH)

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Pulmonary Arterial Hypertension (PAH) Medicine Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Pulmonary Arterial Hypertension (PAH) Medicine Outlook to 2028- Original Forecasts

    • 2.2 Pulmonary Arterial Hypertension (PAH) Medicine Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Pulmonary Arterial Hypertension (PAH) Medicine Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Pulmonary Arterial Hypertension (PAH) Medicine Market- Recent Developments

    • 6.1 Pulmonary Arterial Hypertension (PAH) Medicine Market News and Developments

    • 6.2 Pulmonary Arterial Hypertension (PAH) Medicine Market Deals Landscape

    7 Pulmonary Arterial Hypertension (PAH) Medicine Raw Materials and Cost Structure Analysis

    • 7.1 Pulmonary Arterial Hypertension (PAH) Medicine Key Raw Materials

    • 7.2 Pulmonary Arterial Hypertension (PAH) Medicine Price Trend of Key Raw Materials

    • 7.3 Pulmonary Arterial Hypertension (PAH) Medicine Key Suppliers of Raw Materials

    • 7.4 Pulmonary Arterial Hypertension (PAH) Medicine Market Concentration Rate of Raw Materials

    • 7.5 Pulmonary Arterial Hypertension (PAH) Medicine Cost Structure Analysis

      • 7.5.1 Pulmonary Arterial Hypertension (PAH) Medicine Raw Materials Analysis

      • 7.5.2 Pulmonary Arterial Hypertension (PAH) Medicine Labor Cost Analysis

      • 7.5.3 Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Expenses Analysis

    8 Global Pulmonary Arterial Hypertension (PAH) Medicine Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Export by Region (Top 10 Countries) (2017-2028)

    9 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Outlook by Types and Applications to 2022

    • 9.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Endothelin Receptor Antagonists (ERA) Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Prostacyclin And Prostacyclin Analogs Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Phosphodiesterase 5 (PDE-5) Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Soluble Guanylate Cyclase (SGC) Stimulators Consumption and Growth Rate (2017-2022)

    • 9.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Secondary Pulmonary Hypertension (SPH) Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Primary Pulmonary Hypertension (PPH) Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Outlook till 2022

    • 10.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.2.2 Canada Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.2.3 Mexico Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.2 UK Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.3 Spain Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.4 Belgium Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.5 France Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.6 Italy Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.7 Denmark Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.8 Finland Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.9 Norway Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.10 Sweden Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.11 Poland Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.12 Russia Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.3.13 Turkey Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.4.2 Japan Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.4.3 India Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.4.4 South Korea Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.4.5 Pakistan Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.4.6 Bangladesh Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.4.7 Indonesia Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.4.8 Thailand Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.4.9 Singapore Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.4.10 Malaysia Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.4.11 Philippines Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.4.12 Vietnam Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.5.2 Colombia Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.5.3 Chile Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.5.4 Argentina Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.5.5 Venezuela Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.5.6 Peru Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.5.7 Puerto Rico Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.5.8 Ecuador Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.6.2 Kuwait Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.6.3 Oman Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.6.4 Qatar Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.7.2 South Africa Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.7.3 Egypt Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.7.4 Algeria Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

      • 10.8.2 New Zealand Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    11 Global Pulmonary Arterial Hypertension (PAH) Medicine Competitive Analysis

    • 11.1 Bayer HealthCare

      • 11.1.1 Bayer HealthCare Company Details

      • 11.1.2 Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

      • 11.1.4 Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Pfizer

      • 11.2.1 Pfizer Company Details

      • 11.2.2 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

      • 11.2.4 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Actelion Pharmaceuticals

      • 11.3.1 Actelion Pharmaceuticals Company Details

      • 11.3.2 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

      • 11.3.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 United Therapeutics Corporation

      • 11.4.1 United Therapeutics Corporation Company Details

      • 11.4.2 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

      • 11.4.4 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 GlaxoSmithKline

      • 11.5.1 GlaxoSmithKline Company Details

      • 11.5.2 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

      • 11.5.4 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Gilead Sciences

      • 11.6.1 Gilead Sciences Company Details

      • 11.6.2 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

      • 11.6.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Arena Pharmaceuticals

      • 11.7.1 Arena Pharmaceuticals Company Details

      • 11.7.2 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

      • 11.7.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    12 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Outlook by Types and Applications to 2028

    • 12.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Endothelin Receptor Antagonists (ERA) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Prostacyclin And Prostacyclin Analogs Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Phosphodiesterase 5 (PDE-5) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Soluble Guanylate Cyclase (SGC) Stimulators Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Secondary Pulmonary Hypertension (SPH) Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Primary Pulmonary Hypertension (PPH) Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Outlook to 2028

    • 13.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.2.2 Canada Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.2 UK Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.3 Spain Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.5 France Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.6 Italy Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.8 Finland Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.9 Norway Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.11 Poland Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.12 Russia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.4.2 Japan Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.4.3 India Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.5.3 Chile Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.5.6 Peru Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.6.3 Oman Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Pulmonary Arterial Hypertension (PAH) Medicine

    • Figure of Pulmonary Arterial Hypertension (PAH) Medicine Picture

    • Table Global Pulmonary Arterial Hypertension (PAH) Medicine Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Pulmonary Arterial Hypertension (PAH) Medicine Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Endothelin Receptor Antagonists (ERA) Consumption and Growth Rate (2017-2022)

    • Figure Global Prostacyclin And Prostacyclin Analogs Consumption and Growth Rate (2017-2022)

    • Figure Global Phosphodiesterase 5 (PDE-5) Consumption and Growth Rate (2017-2022)

    • Figure Global Soluble Guanylate Cyclase (SGC) Stimulators Consumption and Growth Rate (2017-2022)

    • Figure Global Secondary Pulmonary Hypertension (SPH) Consumption and Growth Rate (2017-2022)

    • Figure Global Primary Pulmonary Hypertension (PPH) Consumption and Growth Rate (2017-2022)

    • Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Country (2017-2022)

    • Table North America Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Country (2017-2022)

    • Figure United States Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Canada Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Mexico Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Table Europe Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Country (2017-2022)

    • Figure Germany Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure UK Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Spain Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Belgium Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure France Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Italy Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Denmark Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Finland Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Norway Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Sweden Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Poland Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Russia Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Turkey Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Table APAC Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Country (2017-2022)

    • Figure China Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Japan Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure India Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure South Korea Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Thailand Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Singapore Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Philippines Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Table South America Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Country (2017-2022)

    • Figure Brazil Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Colombia Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Chile Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Argentina Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Peru Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Table GCC Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Country (2017-2022)

    • Figure Bahrain Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Oman Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Qatar Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Table Africa Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Country (2017-2022)

    • Figure Nigeria Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure South Africa Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Egypt Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Algeria Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Table Oceania Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Country (2017-2022)

    • Figure Australia Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Table Bayer HealthCare Company Details

    • Table Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

    • Table Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

    • Table Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

    • Table Actelion Pharmaceuticals Company Details

    • Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

    • Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

    • Table United Therapeutics Corporation Company Details

    • Table United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

    • Table United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

    • Table GlaxoSmithKline Company Details

    • Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

    • Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

    • Table Gilead Sciences Company Details

    • Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

    • Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

    • Table Arena Pharmaceuticals Company Details

    • Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Main Business and Markets Served

    • Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio

    • Figure Global Endothelin Receptor Antagonists (ERA) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Prostacyclin And Prostacyclin Analogs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Phosphodiesterase 5 (PDE-5) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Soluble Guanylate Cyclase (SGC) Stimulators Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Secondary Pulmonary Hypertension (SPH) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Primary Pulmonary Hypertension (PPH) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast by Country (2022-2028)

    • Table North America Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast by Country (2022-2028)

    • Figure United States Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast by Country (2022-2028)

    • Figure Germany Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast by Country (2022-2028)

    • Figure China Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast by Country (2022-2028)

    • Figure Brazil Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast by Country (2022-2028)

    • Figure Australia Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US